• Titan Pharmaceuticals has announced that the FDA has granted fast track designation for Spheramine for the treatment of advanced Parkinson’s disease. Spheramine consists of normal, human retinal pigment epithelial cells adhered to spherical microscopic carriers.
  • Peninsula Pharmaceuticals has announced that patient enrollment has begun in the final Phase III trial of its lead product candidate, doripenem. Doripenem, a broad-spectrum antibiotic, is a new member of the carbapenem class of beta-lactam antibiotics. This trial will compare the safety and efficacy of intravenous doripenem with that of intravenous imipenem in patients with ventilator-associated pneumonia.
  • PTC Therapeutics has announced the initiation of a Phase I clinical trial of PTC124 to evaluate the drug’s safety, tolerability, and pharmacokinetic profile. PTC124 is a small-molecule drug that is being investigated initially as a treatment for cystic fibrosis and Duchenne muscular dystrophy.